What one share of XBiotech holds
XBiotech Inc. (“XBiotech” or the “Company”) is a biopharmaceutical company that discovers and develops True Human™ monoclonal antibodies for treating a variety of diseases. XBiotech was incorporated in Canada on March 22, 2005.
XBiotech’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.48 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.34 |
| Cash and investments | $3.59 |
| Book value | $4.21 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2013 | — | −$0.45 | $0.00 | −$0.40 | — | $0.46 |
| 2014 | — | −$0.90 | $0.06 | −$0.54 | — | $2.14 |
| 2015 | — | −$1.22 | $0.08 | −$1.16 | — | $3.19 |
| 2016 | — | −$1.63 | $0.15 | −$1.57 | — | $1.81 |
| 2017 | — | −$0.95 | $0.04 | −$1.01 | — | $1.70 |
| 2018 | $0.00 | −$0.59 | $0.00 | −$0.47 | — | $1.15 |
| 2019 | $0.00 | $14.44 | $0.00 | −$0.40 | — | $18.20 |
| 2020 | $1.43 | −$0.36 | $0.12 | −$2.23 | — | $11.90 |
| 2021 | $0.61 | −$0.58 | $0.12 | $2.19 | — | $8.85 |
| 2022 | $0.13 | −$1.08 | $0.02 | −$0.51 | — | $7.90 |
| 2023 | $0.00 | −$0.81 | $0.01 | −$0.63 | — | $7.19 |
| 2024 | — | −$1.26 | $0.04 | −$1.06 | — | $5.98 |
| 2025 | — | −$1.49 | $0.01 | −$1.32 | — | $4.60 |
Common questions about XBiotech
How much does one share of XBiotech earn?
Over the last 12 months, XBiotech lost $1.48 for each share.
Does XBiotech pay a dividend?
XBiotech didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is XBiotech’s book value per share?
XBiotech’s book value is $4.21 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of XBiotech have?
Each share of XBiotech has $3.59 of cash and investments, as of June 30, 2026.
What is XBiotech’s free cash flow per share?
−$1.34 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has XBiotech bought back shares?
XBiotech’s share count rose about 37% from 2013 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.